RNAZ (TransCode Therapeutics) Gross Profit Margin

RNAZ (TransCode Therapeutics) - company brandmark

TransCode Therapeutics (RNAZ) is developing RNA-based drugs through synergy with institutes and the acquisition of biolabs. High FDA testing costs and patent protection create a significant barrier to entry. The target gross margin demonstrates production efficiency, where the 0.00 level reflects the current magnitude. Intellectual capital regarding the delivery of molecules into tumors will ensure future monetization through licensing agreements.

RNAZ (TransCode Therapeutics, Inc.) Gross Margin history from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for transcodetherapeutics.com (RNAZ)

Summary company analysis:TransCode Therapeutics
Product sample of TransCode Therapeutics

TransCode Therapeutics' extensive clinical trial expenditures make the control of direct costs a critical survival factor. An analysis of the gross margin allows for an assessment of the monetization efficiency of RNA therapy delivery patents by subtracting the cost of goods sold from total revenue. The stable trend on this chart confirms the ability of the company's intellectual moat to generate sufficient cash flow to protect capital from inflation.

Key competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|Gross Profitability Boundless Bio Inc.|Return on Gross Profit Exicure (XCUR)|Gross Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Gross Profit Rate|Mustang Bio, Inc. - Return on Gross Profit|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability